A
3.27
0.07 (2.19%)
| Previous Close | 3.20 |
| Open | 3.24 |
| Volume | 699,572 |
| Avg. Volume (3M) | 874,780 |
| Market Cap | 619,638,848 |
| Price / Sales | 88.00 |
| Price / Book | 5.83 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -1,304.78% |
| Diluted EPS (TTM) | -0.430 |
| Quarterly Revenue Growth (YOY) | -71.30% |
| Total Debt/Equity (MRQ) | 6.32% |
| Current Ratio (MRQ) | 7.02 |
| Operating Cash Flow (TTM) | -71.83 M |
| Levered Free Cash Flow (TTM) | -39.81 M |
| Return on Assets (TTM) | -32.83% |
| Return on Equity (TTM) | -67.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arbutus Biopharma Corporation | Bearish | Bearish |
AIStockmoo Score
-0.4
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.22% |
| % Held by Institutions | 53.84% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Whitefort Capital Management, Lp | 30 Sep 2024 | 12,867,967 |
| Two Seas Capital Lp | 30 Sep 2024 | 8,387,388 |
| Blackbarn Capital Partners Lp | 30 Sep 2024 | 2,070,900 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (Chardan Capital, 52.91%) | Buy |
| 5.00 (HC Wainwright & Co., 52.91%) | Buy | |
| Median | 5.00 (52.91%) | |
| Average | 5.00 (52.91%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 20 Nov 2024 | 5.00 (52.91%) | Buy | 3.44 |
| 06 Nov 2024 | 4.50 (37.61%) | Buy | 3.92 | |
| HC Wainwright & Co. | 18 Nov 2024 | 5.00 (52.91%) | Buy | 3.52 |
| 07 Nov 2024 | 5.00 (52.91%) | Buy | 3.73 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |